MedTrace Logo

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

NCT00402987 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2021-03-03

Study results available
· View outcomes & findings →

Summary

We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.

Conditions

  • Pharyngitis

Interventions

DRUG

Celecoxib

dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

DRUG

Celecoxib

dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo

DRUG

celecoxib

dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

DRUG

placebo

dose 1 placebo followed 6-12 hours later by dose 2 placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-04
Primary Completion
2007-11-15
Completion
2007-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00402987 on ClinicalTrials.gov